Ultragenyx (RARE) | Stock Overview & Key Data
Ultragenyx Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $179.65 on December 21, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ultragenyx RARE | 3.51B Mid-cap | 8.71% | 6.43% | 26.92% | -9.69% | -4.20% | -12.25% | -38.83% | -53.88% |
| Vertex VRTX | 114.06B Large-cap | 3.14% | 4.53% | -1.27% | 13.16% | 14.93% | -6.00% | 56.88% | 55.98% |
| Regeneron REGN | 55.27B Large-cap | 2.40% | 5.82% | -1.63% | -25.33% | -23.41% | -51.08% | -11.43% | -16.45% |
| Blueprint Medicines BPMC | 8.29B Mid-cap | 0.05% | 0.34% | 62.08% | 41.67% | 47.25% | 9.02% | 139.78% | 65.31% |
| Roivant Sciences ROIV | 7.82B Mid-cap | -0.73% | -1.99% | 19.60% | -1.45% | -10.10% | -5.37% | 151.52% | 8.27% |
| Bio-Techne TECH | 7.92B Mid-cap | 1.15% | 5.61% | 7.93% | -29.94% | -26.30% | -33.33% | -40.13% | -26.31% |
Ultragenyx Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ultragenyx would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is RARE's 52-week high and low?
In the last 52 weeks, Ultragenyx reached a high of $60.37 (on September 16, 2024) and a low of $29.59 (on April 9, 2025).
What is the market cap and P/E ratio for RARE?
Curious about Ultragenyx's size and valuation? Its market capitalization stands at 3.51B. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.91, and the forward P/E (looking ahead) is N/A.
Does RARE pay dividends? If so, what's the yield?
As for dividends, Ultragenyx isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Ultragenyx's main competitors or similar companies to consider before investing?
When looking at Ultragenyx, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Vertex VRTX | 114.06B | Healthcare | Biotechnology | -6.00% | 56.88% |
| Regeneron REGN | 55.27B | Healthcare | Biotechnology | -51.08% | -11.43% |
| Blueprint Medicines BPMC | 8.29B | Healthcare | Biotechnology | 9.02% | 139.78% |
| Roivant Sciences ROIV | 7.82B | Healthcare | Biotechnology | -5.37% | 151.52% |
| Bio-Techne TECH | 7.92B | Healthcare | Biotechnology | -33.33% | -40.13% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Ultragenyx Pharmaceutical Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Ultragenyx's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is N/A, the Debt to Equity ratio from the most recent quarter is N/A, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for RARE?
Looking at Ultragenyx's growth, its revenue over the trailing twelve months (TTM) was N/A. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
How much of RARE stock is held by insiders and institutions?
Wondering who owns Ultragenyx stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.